Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 7 | Molecular Cancer

Figure 7

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

Figure 7

The antioxidant NAC reduces cell death induced by either cisplatin, Mapatumumab or a combination thereof. The MPM cell lines H28, ZL55 and ZL34 were treated with cisplatin (6.61 μM, 6.0 μM, and 6.0 uM, respectively) and 24 h later with Mapatumumab (0.13 μg/ml, 10 μg/ml, 10 μg/ml, respectively) as indicated, either in the presence or absence of NAC (5 mM). Cell proliferation was determined by MTT assay 48 h thereafter. Absorbance values obtained with untreated cells maintained under identical conditions were taken as 100%. Data represent means of at least three independent experiments and bars indicate standard deviations. **, P < 0.01 and *, P < 0.05 compared to cells treated in the absence of NAC but otherwise maintained under identical conditions.

Back to article page